Canada approves pegfilgrastim biosimilar Pexegra

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Canada approves pegfilgrastim biosimilar Pexegra

Biosimilares/Novedades | Posted 21/03/2025 0 Post your comment

On 25 February 2025, Health Canada granted marketing authorization to India-based Kashiv BioSciences for its pegfilgrastim biosimilar, Pexegra, which references Amgen’s Neulasta (pegfilgrastim).

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim. It stimulates the production of white blood cells (neutrophils). Pegfilgrastim treatment is used to encourage bone marrow to produce more neutrophils to help fight infection in patients undergoing chemotherapy [1].

Pexegra is a long-acting G-CSF biosimilar indicated for reducing incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive antineoplastic therapy.

The marketing authorization was granted following a rigorous regulatory review by Health Canada, ensuring that Kashiv’s pegfilgrastim Injection meets the stringent quality, safety, and efficacy standards comparable to the reference biological.

Pexegra will be distributed and commercialised in Canada by Kashiv’s licensing partner, Jamp Pharma Group.

Kashiv has already received regulatory success with its filgrastim biosimilar Releuko (filgrastim-ayow), which was approved by the US Food and Drug Administration in March 2022 [2].

Additionally, Kashiv completed a global phase I clinical study in healthy volunteers for its biosimilar candidate, ADL018, referencing Xolair (omalizumab), in late 2023 [3].

In a related development, India-based Lupin received marketing approval from Health Canada for its biosimilar pegfilgrastim, Armlupeg, on 23 August 2024 [4].

Related articles
January 2025 biosimilar approvals in Europe

Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals

Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement

LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: IFPMA publica su posición sobre la sustitución de biosimilares mediada por farmacias

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: IFPMA publica su posición sobre la sustitución de biosimilares mediada por farmacias

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of pegfilgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Mar 21]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-pegfilgrastim
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves Kashiv Biosciences’ filgrastim biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Mar 21]. Available from:
www.gabionline.net/biosimilars/news/fda-approves-kashiv-biosciences-filgrastim-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. Clinical trial advances for Kashiv and Celltrion [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Mar 21]. Available from: www.gabionline.net/biosimilars/research/clinical-trial-advances-for-kashiv-and-celltrion
4. GaBI Online - Generics and Biosimilars Initiative. Canada approves pegfilgrastim biosimilar Armlupeg [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Mar 21]. Available from:
www.gabionline.net/biosimilars/research/clinical-trial-advances-for-kashiv-and-celltrion

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.